Connexion
Connexion
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Inscription
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Accueil Zonebourse
  2. Actions
  3. France
  4. Euronext Paris
  5. Pharnext SA
  6. Actualités
  7. Autres langues
    ALPHA   FR001400BV89

PHARNEXT SA

(ALPHA)
  Rapport
Cours en clôture Euronext Paris  -  09/12/2022
0.1026 EUR   +1.38%
28/11Pharnext : démission avec effet immédiat du DG David Solomon
CF
28/11Chine, le ras-le-bol sanitaire
ZB
28/11Le directeur général de Pharnext démissionne ; le président est nommé directeur général par intérim
MT
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur PHARNEXT SA
29/11Pharnext : corporate presentation
29/11Pharnext : Présentation corporate de Pharnext
28/11Pharnext Chief Executive Steps Down; Chair Named Interim CEO
28/11Pharnext SA Announces Director Changes
28/11Pharnext SA Announces Executive Changes
28/11Pharnext : The Board of Directors of Pharnext acknowledges the resignation of Dr. David Ho..
23/11Bolsa de Madrid: ¿Demasiadas estadísticas antes del pavo?
22/11Pharnext : completion of the reverse split of its shares on the basis of 1 new share for 5..
08/11Hugo Brugière Joins Pharnext Board of Directors
08/11Hugo Brugière Joins Pharnext Board of Directors
31/10Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext se..
17/10Pharnext Reports First Half 2022 Financial Results
17/10Pharnext SA Reports Earnings Results for the Half Year Ended June 30, 2022
04/10Bolsa de Madrid: El mercado intenta una nueva partitura
04/10Pharnext To Carry Out Reverse Stock Split
03/10Pharnext announces a reverse stock split and suspension of the right to exercise all th..
03/10Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to furthe..
30/09Pharnext SA announced that it expects to receive €21.0938 million in funding from ..
15/09Pharnext : Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘R..
14/09Pharnext SA Announces the Publication of Symptom Burden Findings of Charcot-Marie-Tooth..
14/09Pharnext : Findings From ‘Real-World' Digital Lifestyle Study, CMT&Me, on Symptom Bu..
12/09Pharnext Surges 14% as First Patient Enrolls for Charcot-Marie-Tooth Disease Treatment ..
12/09Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase ..
12/09Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase ..
01/09Pharnext : Présentation Corporate de Pharnext
01/09Pharnext Appoints Dr. Rob Quinn as Chief Financial Officer
23/08Pharnext Shares Drop 6% Amid $3 Million Loan from Néovacs
23/08Pharnext Announces a €2.5m Loan Agreement with Néovacs
08/08Pharnext Soars 13% On Potential $20 Million Investment From Neovacs
05/07Pharnext Appoints Antoine Gravelle as General Counsel
20/06Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Dire..
08/06Pharnext Secures $13 Million Loan To Pay Down Existing Debt
08/06Pharnext Announces Successful Debt Refinancing and New Loan Agreement
30/05Pharnext Shares Up 24% On Completion Of Patients' Enrollment For CMT1A Treatment Clinic..
30/05Pharnext : Présentation Corporate de Pharnext
30/05Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase II..
16/05New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in ..
16/05De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de P..
16/05De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de P..
16/05New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in ..
16/05Pharnext Announces New Results from the Ongoing Open-Label Follow-Up Extension Study of..
05/05Pharnext : The Latest Findings From CMT&Me, a ?Real-World? Digital Lifestyle Study on Char..
26/04Pharnext : Présentation Corporate de Pharnext
25/04Pharnext SA Reports Earnings Results for the Full Year Ended December 31, 2021
25/04Pharnext : Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates
31/03Pharnext's Chair Quits; Names Interim Successor
30/03Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
02/03Pharnext : Présentation Corporate de Pharnext
16/02Pharnext Names New CFO
15/02Pharnext appoints Valérie Worrall as Chief Financial Officer
03/01Pharnext : Présentation Corporate de Pharnext
2021Pharnext Sa Appoints Elisabeth Svanberg as Chairman of Board of Directors
2021Pharnext Names New Chair, Shares Surge 12%
2021Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chair..
2021Pharnext To Halt Convertible Bond Financing By May 2022 End
2021Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from E..
2021Global markets live: Samsung, Clariant, AstraZeneca, Amazon, Merck....
2021Pharnext SA Appoints Dr. Burkhard Blank as New Chief Medical Officer and Head of Resear..
2021Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research ..
2021Présentation du R&D Day 2021
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Names Chief Manufacturing Officer, COO; Shares Up 17%
2021Pharnext : Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Dise..
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext :
2021Pharnext : Piers Morgan Joins Pharnext's Board of Directors
2021Pharnext : Enrolls First Patient in European Phase 3 Study of Rare Genetic Diso..
2021Pharnext : Shareholder Letter
2021Pharnext : Letter to Shareholders
2021Opiniones de los analistas del día: Telefónica, BMW, ..
2021Global markets live: Toshiba, Facebook, AT&T, Tesla, Blackstone...
2021¿La gran noche fiscal para las multinacionales?
2021Pharnext : Announces a New Financing Through a Convertible Bond Program for a Total Amount..
2021Pharnext : Announces a New Financing Through a Convertible Bond Program for a Total Amount..
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Auditors' report on Financial year 2020
2021Pharnext : Auditors' report on IFRS Financial statement 2020
2021Pharnext : Presentation of the PLEO-CMT-FU Extension Study Update
2021EN DIRECTO DESDE LOS MERCADOS: Nokia, Apple, Facebook, Log..
2021Para la Fed, es urgente esperar
2021Pharnext SA Announces New Results from an Interim Analysis from the Ongoing Open-Label ..
2021Pharnext : Une analyse intermédiaire de l'étude de Phase III d'extension en ouvert en cour..
2021Pharnext : Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Su..
2021Global markets live: Microsoft, Apple, Tesla...
2021Pharnext : 2020 Annual Financial results IFRS
2021Pharnext : French Gaap Financial Statement 2020
2021Pharnext : Reports Financial Results for Year-End 2020
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Enrolls First Patient In Phase III Trial to Treat Neurological Disor..
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Cl..
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Présentation Corporate de Pharnext
2021Pharnext : Announces Financing of €11 Million Through a Capital Raise Subscribed by Existi..
2021Pharnext : Announces Financing of ?11 Million Through a Capital Raise Subscribed by Existi..
2021Pharnext SA announced that it expects to receive €10.999997 million in funding from CB ..
2021Pharnext : Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie..
2021Pharnext : Présentation Corporate de Pharnext
Prochain événement sur PHARNEXT SA